1. Home
  2. CPIX vs GLYC Comparison

CPIX vs GLYC Comparison

Compare CPIX & GLYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPIX
  • GLYC
  • Stock Information
  • Founded
  • CPIX 1999
  • GLYC 2003
  • Country
  • CPIX United States
  • GLYC United States
  • Employees
  • CPIX N/A
  • GLYC N/A
  • Industry
  • CPIX Biotechnology: Pharmaceutical Preparations
  • GLYC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPIX Health Care
  • GLYC Health Care
  • Exchange
  • CPIX Nasdaq
  • GLYC Nasdaq
  • Market Cap
  • CPIX 17.2M
  • GLYC 19.5M
  • IPO Year
  • CPIX 2009
  • GLYC 2014
  • Fundamental
  • Price
  • CPIX $2.36
  • GLYC $0.23
  • Analyst Decision
  • CPIX
  • GLYC Hold
  • Analyst Count
  • CPIX 0
  • GLYC 3
  • Target Price
  • CPIX N/A
  • GLYC $12.00
  • AVG Volume (30 Days)
  • CPIX 5.5M
  • GLYC 1.2M
  • Earning Date
  • CPIX 11-07-2024
  • GLYC 01-06-2025
  • Dividend Yield
  • CPIX N/A
  • GLYC N/A
  • EPS Growth
  • CPIX N/A
  • GLYC N/A
  • EPS
  • CPIX N/A
  • GLYC N/A
  • Revenue
  • CPIX $36,785,442.00
  • GLYC $10,000.00
  • Revenue This Year
  • CPIX N/A
  • GLYC N/A
  • Revenue Next Year
  • CPIX N/A
  • GLYC N/A
  • P/E Ratio
  • CPIX N/A
  • GLYC N/A
  • Revenue Growth
  • CPIX N/A
  • GLYC N/A
  • 52 Week Low
  • CPIX $1.04
  • GLYC $0.14
  • 52 Week High
  • CPIX $3.05
  • GLYC $3.53
  • Technical
  • Relative Strength Index (RSI)
  • CPIX 66.16
  • GLYC 36.58
  • Support Level
  • CPIX $2.07
  • GLYC $0.21
  • Resistance Level
  • CPIX $2.93
  • GLYC $0.34
  • Average True Range (ATR)
  • CPIX 0.26
  • GLYC 0.03
  • MACD
  • CPIX 0.08
  • GLYC -0.01
  • Stochastic Oscillator
  • CPIX 53.06
  • GLYC 17.19

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

About GLYC GlycoMimetics Inc.

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Share on Social Networks: